Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children

Pediatric Transplantation

Volumn 14, Issue 6, 2010, Pages 746-752

  Reyes, H ^a   Hernandez A M ^a   Valverde, S ^a   Cataneo, A ^a   Mendoza, A ^a   Barrera, I ^a   Ortiz L ^a   Garcia Roca P ^a   Lopez Martinez B ^a   Castaneda Hernandez G ^b   Medeiros, M ^a  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

gene expression; GSRS; IMPDH; pediatric; pharmacokinetics; real time PCR

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOSPORIN; GLUCURONIDE; HEMOGLOBIN; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE 2; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SERUM ALBUMIN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEDTIME DOSAGE; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; BLOOD EXAMINATION; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENTERIC COATED TABLET; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL REFLUX; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEMATOCRIT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDIGESTION; KIDNEY FUNCTION TEST; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LIVER FUNCTION TEST; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MAXIMUM PLASMA CONCENTRATION; MEDICAL EXAMINATION; PROSPECTIVE STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; AREA UNDER CURVE; CHILD; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; TABLETS, ENTERIC-COATED;

EID: 77955789883     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2010.01326.x     Document Type: Article

References (32)

1. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005 : 80 : S181 S190.
2. Ettenger R, Bartosh S, Choi L, et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatr Transplant 2005 : 9 : 780 787.
3. Laouad I, Halimi JM, Buchler M, et al. Recipient age and mycophenolate mofetil as the main determinants of outcome after steroid withdrawal: Analysis of long-term follow-up in renal transplantation. Transplantation 2005 : 80 : 872 874.
4. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007 : 46 : 13 58.
5. Hesselink DA, Van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 2005 : 78 : 317 321.
6. Van Hest RM, Mathot RA, Vulto AG, Ijzermans JN, Van Gelder T. Within-patient variability of mycophenolic acid exposure: Therapeutic drug monitoring from a clinical point of view. Ther Drug Monit 2006 : 28 : 31 34.
7. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: A report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002 : 13 : 759 768.
8. Bremer S, Vethe NT, Rootwelt H, Bergan S. Expression of IMPDH1 is regulated in response to mycophenolate concentration. Int Immunopharmacol 2009 : 9 : 173 180.
9. Sombogaard F, Peeters AM, Baan CC, et al. Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. Ther Drug Monit 2009 : 31 : 549 556.
10. Bolin P, Tanriover B, Zibari GB, et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 2007 : 84 : 1443 1451.
11. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management. Drug Saf 2001 : 24 : 645 663.
12. Van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005 : 80 : S244 S253.
13. Nart A, Sipahi S, Aykas A, Uslu A, Hoscoskun C, Toz H. Efficacy and safety of enteric-coated mycophenolate sodium in de novo and maintenance renal transplant patients. Transplant Proc 2008 : 40 : 189 192.
14. United States Patent. Patent Number 6,306,900 B1. Enteric coated pharmaceutical compositions. Available at: http://www.google.com.mx/patents?id= DA8IAAAAEBAJ&printsec=claims&zoomv=onepage&q=&f=false. (accessed January, 25, 2010).
15. Budde K, Knoll G, Curtis J, et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Clin Nephrol 2006 : 66 : 103 111.
16. Zimmerhackl LB, Jungraithmayr T, Wiesmayr S, Filler G. Myfortic in pediatric transplantation. Pediatr Transplant 2008 : 12 : 614 616.
17. Pape L, Ahlenstiel T, Kreuzer M, Ehrich JH. Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children. Pediatr Transplant 2008 : 12 : 640 642.
18. Niaudet P, Charbit M, Loirat C, et al. Enteric-coated mycophenolate sodium in de novo pediatric renal transplant patients. Pediatr Nephrol 2009 : 24 : 395 402.
19. Machnicki G, Pefaur J, Gaite L, et al. Gastrointestinal (GI)-Specific patient reported outcomes instruments differentiate between renal transplant patients with or without GI symptoms: Results from a South American cohort. Health Qual Life Outcomes 2008 : 6 : 53.
20. Schwartz GJ, Furth SL. Glomerular filtration rate measurement and estimation in chronic kidney disease. Pediatr Nephrol 2007 : 22 : 1839 1848.
21. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005 : 353 : 2342 2351.
22. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008 : 8 : 753 760.
23. Ferraris JR, Tambutti ML, Prigoshin N, Grosman M, Cardoni RL. Conversion from mycophenolate mofetil to delayed formulation in pediatric renal transplantation: Higher mycophenolic acid predose level but no changes in the immune biomarkers. Pediatr Transplant 2009 : 13 : 731 736.
24. Kiberd BA. Post-transplant erythrocytosis: A disappearing phenomenon? Clin Transplant 2008 : 23 : 800 806.
25. Heller T, Geide A, Bonitz U, et al. Effect of the antioxidant idebenone on adverse events under mycophenolate mofetil therapy in a rat model. Transplantation 2008 : 85 : 739 747.
26. Kamar N, Rostaing L. Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation 2008 : 85 : 1120 1124.
27. Budde K, Tedesco-Silva H, Pestana JM, et al. Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: Implications for therapeutic drug monitoring. Ther Drug Monit 2007 : 29 : 381 384.
28. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 2008 : 85 : 1675 1685.
29. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006 : 82 : 102 107.
30. Davies NM, Grinyo J, Heading R, Maes B, Meier-Kriesche HU, Oellerich M. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: A reappraisal. Nephrol Dial Transplant 2007 : 22 : 2440 2448.
31. Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: A consequence of local GI toxicity? Transplant Proc 2007 : 39 : 88 93.
32. Yang JW, Lee PH, Hutchinson IV, Pravica V, Shah T, Min DI. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Ther Drug Monit 2009 : 31 : 542 548.